These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22395682)

  • 21. Clinical forecasting in drug development.
    Schachter AD; Ramoni MF
    Nat Rev Drug Discov; 2007 Feb; 6(2):107-8. PubMed ID: 17342862
    [No Abstract]   [Full Text] [Related]  

  • 22. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME
    N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
    [No Abstract]   [Full Text] [Related]  

  • 23. New models for pharmaceutical innovation in low-income countries.
    Ardal C; Iversen JH; Myhr K
    Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2016-8. PubMed ID: 22016131
    [No Abstract]   [Full Text] [Related]  

  • 24. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs for rare diseases: influence of orphan designation status on price.
    Picavet E; Dooms M; Cassiman D; Simoens S
    Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantifying emerging drugs for very rare conditions.
    Miles KA; Packer C; Stevens A
    QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New startup models emerge as investor landscape shifts.
    Huggett B
    Nat Biotechnol; 2011 Dec; 29(12):1066-7. PubMed ID: 22158350
    [No Abstract]   [Full Text] [Related]  

  • 28. R&D policy, agency costs and innovation in personalized medicine.
    Yin W
    J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Germany's Novartis Chief proposes "More competition through decentralized contracts"].
    Kosche D; Färber L
    MMW Fortschr Med; 2010 Aug; 152(31-33):6-7. PubMed ID: 20828056
    [No Abstract]   [Full Text] [Related]  

  • 30. Uncommon ventures launch to tackle uncommon diseases.
    Dolgin E
    Nat Med; 2013 Aug; 19(8):950-1. PubMed ID: 23921728
    [No Abstract]   [Full Text] [Related]  

  • 31. Orphan economics: the downside of supplyside pharmacology.
    Samson K
    Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract]   [Full Text] [Related]  

  • 32. Market watch: pricing strategies for emerging markets.
    Lineberry N; Snyder E; Gunda S
    Nat Rev Drug Discov; 2011 Aug; 10(8):567. PubMed ID: 21804586
    [No Abstract]   [Full Text] [Related]  

  • 33. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S; Compagni A; Reich MR
    Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Issues in bringing new drugs to the market.
    Ammann AJ
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329171
    [No Abstract]   [Full Text] [Related]  

  • 36. Resurrection men dig through the drug graveyard: ARYx revives problem blockbuster drugs.
    Wolfson W
    Chem Biol; 2005 Nov; 12(11):1155-6. PubMed ID: 16298292
    [No Abstract]   [Full Text] [Related]  

  • 37. Aligning needs.
    Ford D; Kohlbrenner W
    Nat Biotechnol; 2016 Mar; 34(3):226-30. PubMed ID: 26963540
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 39. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.